Exploring HER2 Detection in Ovarian Cancer
Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary
This study is trying to find better ways to detect HER2 in ovarian cancer patients to help improve treatment options and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 144 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | Female |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06883487 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the detection of HER2 in patients with high-grade serous adenocarcinoma of the ovary. It aims to establish diagnostic criteria and positive thresholds for HER2 expression, which is crucial for the effectiveness of targeted antibody drug conjugates (ADCs). The study will analyze existing pathological samples to gather data on HER2 expression rates and their implications for treatment outcomes. By addressing the current lack of large-scale data and clear detection standards, the study seeks to improve clinical practices in managing ovarian cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with high-grade serous adenocarcinoma of the ovary who have sufficient pathological samples and complete clinical data.
Not a fit: Patients with low-grade serous adenocarcinoma or those without adequate pathological samples may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of HER2 detection, leading to better-targeted therapies for ovarian cancer patients.
How similar studies have performed: While there is ongoing research into HER2-targeted therapies in ovarian cancer, this study aims to fill a gap in large-scale data and detection standards, making it a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Pathological type: high-grade serous adenocarcinoma of the ovary 2. Pathological slices stored within 5 years 3. FIGO stage II or above 4. Complete clinical and follow-up data Exclusion Criteria: 1. Slice quality control failure 2. Incomplete follow-up data
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — Guangzhou, Guangdong, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.